|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquired
|
Guangzhou Pharmaceutical Holdings Limited
|
|
gptkbp:acquisition
|
China National Pharmaceutical Group Corporation in 2016
|
|
gptkbp:acquisition_year
|
gptkb:2016
|
|
gptkbp:affiliation
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:ceo
|
Liang Zhiqiang
|
|
gptkbp:clinical_trial
|
over 100
multiple countries
COVID-19 vaccine trials
vaccine development
Phase III trials
|
|
gptkbp:collaboration
|
global health initiatives
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:community_engagement
|
healthcare initiatives
|
|
gptkbp:community_health
|
public health programs
significant impact on global health
|
|
gptkbp:distribution_channels
|
national distribution network
|
|
gptkbp:economic_impact
|
international markets
|
|
gptkbp:employees
|
over 30,000
|
|
gptkbp:established
|
gptkb:2003
|
|
gptkbp:founded
|
gptkb:2003
|
|
gptkbp:global_presence
|
over 100 countries
|
|
gptkbp:headquarters
|
gptkb:Beijing
gptkb:Beijing,_China
|
|
gptkbp:healthcare
|
generic drugs
new healthcare technologies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinopharm Group Co., Ltd.
|
|
gptkbp:industry
|
healthcare
|
|
gptkbp:investment
|
biotechnology companies
|
|
gptkbp:is_vulnerable_to
|
emergency use authorization
global vaccine distribution
79% efficacy
|
|
gptkbp:key_people
|
Liang Zhiqiang
|
|
gptkbp:market_cap
|
$40 billion (2021)
|
|
gptkbp:net_income
|
$1 billion (2020)
|
|
gptkbp:notable_products
|
Sinopharm COVID-19 vaccine
|
|
gptkbp:operating_income
|
$1.5 billion (2020)
|
|
gptkbp:parent_company
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:partnership
|
gptkb:World_Health_Organization
|
|
gptkbp:partnerships
|
international health organizations
|
|
gptkbp:product_line
|
vaccines and therapeutics
|
|
gptkbp:products
|
vaccines
|
|
gptkbp:regulatory_compliance
|
gptkb:various_countries
|
|
gptkbp:research_and_development
|
vaccine research
|
|
gptkbp:research_focus
|
biopharmaceuticals
|
|
gptkbp:revenue
|
$12 billion (2020)
|
|
gptkbp:services
|
pharmaceutical distribution
|
|
gptkbp:stock_symbol
|
601607. SS
|
|
gptkbp:subsidiaries
|
gptkb:China_National_Pharmaceutical_Group_Corporation
|
|
gptkbp:supply_chain
|
pharmaceutical supply chain
|
|
gptkbp:sustainability_initiatives
|
environmental sustainability
|
|
gptkbp:type
|
gptkb:state-owned_enterprise
|
|
gptkbp:vaccine_production_capacity
|
millions of doses
|
|
gptkbp:website
|
www.sinopharm.com
|
|
gptkbp:bfsParent
|
gptkb:China_National_Pharmaceutical_Group_Corporation
|
|
gptkbp:bfsLayer
|
5
|